Phanes Therapeutics’ spevatamig data puts cold-tumor immunotherapy back in focus at ASCO 2026
See how Phanes Therapeutics’ spevatamig data could reshape metastatic pancreatic cancer drug development after ASCO 2026.
Why CLINCH-3 matters for Antengene’s oncology strategy and gastric cancer ambitions
Antengene’s ATG-022 enters pivotal testing in gastric cancer, testing whether CLDN18.2 ADCs can stand out in a crowded oncology field.
Phanes’ spevatamig shows 40% response rate in mPDAC: How it compares to GnP standard
Phanes’ spevatamig + chemo combo shows 40% ORR in mPDAC. Find out why this bispecific antibody may change frontline pancreatic cancer treatment.